Clinical Evidence
Masimo is passionate about making innovative technologies that give clinicians the tools they need to do what is best for patient care. That's why it is gratifying to see so many independent clinicians and clinical researchers take the time to independently evaluate our products and technologies—and then to communicate the positive impacts on patient care and safety that can be realized through their use.
More than 100 independent and objective studies by researchers around the world have demonstrated the clinical advantages of our technologies. These studies have shown Masimo technologies can provide a dramatic reduction in eye damage in the NICU, accurately measure cyanotic patients at very low oxygen-saturation levels, and much, much more.
Featured Clinical Studies
Accuracy of a Continuous Noninvasive Hemoglobin Monitor in Intensive Care Unit Patients- Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology
Impact of Continuous and Noninvasive Hemoglobin Monitoring on Intraoperative Blood Transfusions- Goal-Directed Fluid Management Based on the Pulse Oximeter-Derived Pleth Variability Index Reduces Lactate Levels and Improves Fluid Management
- Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers
Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns
- Pleth Variability Index to Monitor the Respiratory Variations in the Pulse Oximeter Plethysmographic Waveform Amplitude and Predict Fluid Responsiveness in the Operating Theatre
- Comparison of Three New Generation Pulse Oximeters during Motion & Low Perfusion in Volunteers
- "Motion-Resistant" Pulse Oximetry: A Comparison of New and Old Models
- More Reliable Oximetry Reduces the Frequency of Arterial Blood Gas Analyses and Hastens Oxygen Weaning After Cardiac Surgery
- Reliability of Conventional and New Pulse Oximetry in Neonatal Patients
This section is intended to provide access to independent, objective, third-party, and government-sponsored clinical studies and abstracts conducted using Masimo noninvasive technologies, parameters, and products, which are known to Masimo's marketing department. We cannot guarantee that all clinical studies, abstracts, and research are represented. To view the individual clinical studies and abstracts, please click on the appropriate tab.
While clinical studies and abstracts support the effectiveness of Masimo noninvasive technologies and parameters, individual results may vary. Masimo cannot guarantee specific results achieved or suggested in individual studies. Always strictly follow the directions for use (DFU) found in the product manual. Use of Masimo technologies and parameters may not be appropriate for every individual or clinical condition. Understanding the indications and limitations of use can help you make the best decision for your individual situation.
- Masimo rainbow® Pulse CO-Oximetry™
and Acoustic Monitoring - Masimo SET®
Pulse Oximetry - Patient
SafetyNet™ - SEDLine® Brain
Function Monitoring
Masimo rainbow® Pulse CO-Oximetry and Acoustic Monitoring
A breakthrough technology platform that noninvasively and continuously measures multiple parameters that previously required invasive procedures, including blood constituents, fluid responsiveness, and respiration rate.
- Total Hemoglobin (SpHb®)
SpHb has been shown to help clinicians assess hemoglobin status and determine treatment and additional test options in surgery, critical care, outpatient care areas, and the emergency department. - Pleth Variability Index (PVI®)
PVI provides an indicator of the variability of the perfusion index (PI). - Acoustic Respiration Rate (RRa™)
RRa noninvasively and continuously measures respiration rate. - Carboxyhemoglobin (SpCO®)
SpCO has been shown to help clinicians assess carbon monoxide levels in the blood and determine treatment and additional test options. - Methemoglobin (SpMet®)
SpMet has been shown to help clinicians noninvasively and continuously assess methemoglobinemia status and determine treatment and additional test options.
Clinically proven to provide the most accurate and reliable SpO2, perfusion index (PI), and pulse rate measurements—even under the most challenging conditions of patient motion and low peripheral perfusion—Masimo SET has been shown to reduce false patient monitor alarms by over 95% and expand true alarm detection to over 97%.
Combining Masimo rainbow SET® Pulse CO-Oximetry™ and rainbow® Acoustic Monitoring with wireless clinician notifications via pager or smartphone, Patient SafetyNet provides an unmatched level of safety for up to 80 patients on four floors—facilitating early clinical response to preempt sentinel events and avoid unnecessary ICU transfers.
SEDLine® Brain Function Monitoring
SEDLine brain function monitors feature 4-channels of high-quality EEG data to facilitate immediate detection of asymmetrical activity, rapid assessments, enhanced anesthetic management and control, and more individualized titration that helps clinicians achieve targeted sedation throughout all phases of anesthesia.
© 2012 Masimo Corporation. All rights reserved. Masimo, SET, Signal Extraction Technology, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. All other product names are trademarks or registered trademarks of their respective holders.